Seres Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Cambridge, MA
MCRB chart
What traders are saying about $MCRB
Latest postsSeres Therapeutics, Inc. news
- Weekly Recap: SER-155 reports fewer infections and funding through Q1 2027
TradingView ·
- Seres Therapeutics, Inc. (MCRB) Seasonal Returns Chart - Yahoo Finance
Yahoo! Finance Canada ·
- Seres Therapeutics 3Q 2026: Revenue $593K, Net loss $16.3M, EPS $(1.63) — 10-Q Summary
TradingView ·
- Seres Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- Seres Therapeutics Inc earnings beat by $0.01, revenue fell short of estimates
Investing.com ·
- Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
Yahoo Finance ·
- Seres Therapeutics: Q3 Earnings Snapshot
Yahoo Finance ·
- Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
Yahoo Finance ·
- Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Yahoo Finance ·
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Yahoo Finance ·
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
Yahoo Finance ·
Seres Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M |
| Diluted EPS | $0.64 | $0.00 | $-17.77 | $-2.31 |
| Total assets (year end) | $138.2M | $139.8M | $358.6M | $348.8M |
| Cash and equivalents (year end) | $45.8M | $30.8M | $128.0M | $163.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Seres Therapeutics, Inc.
- Ticker
- MCRB (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1609809
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
Frequently asked questions
What exchange is Seres Therapeutics, Inc. listed on?
Seres Therapeutics, Inc. trades on the Nasdaq under the ticker symbol MCRB.
What industry is Seres Therapeutics, Inc. in?
Seres Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Seres Therapeutics, Inc. headquartered?
Seres Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Seres Therapeutics, Inc.'s fiscal year end?
Seres Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Seres Therapeutics, Inc. report?
Seres Therapeutics, Inc. reported $789,000 in revenue for calendar year 2025, according to its SEC filings.